G6PDH (Quantitative) at Test Zone Diagnostic Center

G6PDH (Quantitative) at Test Zone Diagnostic Center

The G6PDH (Quantitative) test is a specialized laboratory investigation designed to measure the precise enzymatic activity of Glucose-6-Phosphate Dehydrogenase (G6PD) in red blood cells. G6PD is a critical cytosolic enzyme that plays a pivotal role in the pentose phosphate pathway, a metabolic route essential for maintaining cellular redox equilibrium. Specifically, this enzyme catalyzes the conversion of glucose-6-phosphate to 6-phosphoglucono-D-lactone, a reaction coupled with the reduction of nicotinamide adenine dinucleotide phosphate (NADP+) to NADPH. In red blood cells, which lack mitochondria and other organelles, the generation of NADPH is uniquely dependent on this pathway. NADPH is the primary co-factor required to regenerate reduced glutathione, a potent intracellular antioxidant that neutralizes reactive oxygen species (ROS) and protects hemoglobin and erythrocyte membranes from oxidative denaturation. When G6PD activity is deficient, red blood cells become highly susceptible to oxidative stress, leading to premature hemolysis, acute hemolytic anemia, or chronic nonspherocytic hemolytic anemia.

At Test Zone Diagnostic Center in Lahore, Pakistan, the G6PDH (Quantitative) test is performed using state-of-the-art automated clinical biochemistry analyzers. Unlike qualitative screening tests that merely indicate the presence or absence of severe deficiency, the quantitative assay provides an exact numerical value of enzyme activity, typically expressed in units per gram of hemoglobin (U/g Hb). This high level of precision is clinically invaluable, particularly for identifying heterozygous female carriers who may exhibit intermediate enzyme levels due to random X-chromosome inactivation (lyonization). It is also essential for classifying the severity of G6PD deficiency according to the World Health Organization (WHO) guidelines, which range from Class I (severe deficiency with chronic hemolytic anemia) to Class IV (normal activity). Accurate quantitative measurement allows clinicians to make informed decisions regarding patient safety, dietary restrictions, and pharmacological interventions, ultimately preventing life-threatening hemolytic crises.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is critical to ensure the clinical accuracy of the G6PDH (Quantitative) test. Patients must adhere to the following guidelines prior to sample collection:

• Timing of the Test: It is highly recommended to avoid testing during or immediately after an active episode of acute hemolysis. During a hemolytic crisis, older, enzyme-deficient red blood cells are destroyed first, leaving behind a higher proportion of young red blood cells (reticulocytes). Because reticulocytes possess significantly higher G6PD enzyme activity than mature erythrocytes, testing during this period can yield a false-normal result, masking an underlying deficiency. It is generally advised to wait at least 8 to 12 weeks after an acute hemolytic event before undergoing quantitative testing.
• Medication Disclosure: Patients must inform their healthcare provider and the laboratory staff at Test Zone Diagnostic Center of all medications, supplements, and herbal remedies they are currently taking. Certain oxidative drugs, such as antimalarials (e.g., primaquine), sulfonamides, dapsone, and high-dose vitamin C, should be reviewed, as they can trigger hemolysis in deficient individuals and alter the clinical picture.
• Dietary Restrictions: While fasting is not strictly required for this blood test, patients must avoid consuming fava beans (broad beans) prior to the test, especially if they have a suspected or known sensitivity (favism).
• Transfusion History: If the patient has recently received a blood transfusion, the test should be postponed for at least 3 months. A recent transfusion introduces donor red blood cells with normal G6PD levels into the patient’s circulation, which will falsely elevate the quantitative test results.

During the Procedure

The G6PDH (Quantitative) test is a standard venipuncture procedure performed by highly trained phlebotomists at Test Zone Diagnostic Center. The process is quick, safe, and designed to minimize patient discomfort:

• Patient Positioning: The patient is comfortably seated, and the phlebotomist identifies a suitable vein, typically in the antecubital fossa (the inner bend of the elbow).
• Sanitization: The skin over the selected vein is thoroughly cleansed with an antiseptic swab (usually 70% isopropyl alcohol) and allowed to air dry to prevent specimen contamination.
• Sample Collection: A sterile, single-use needle is inserted into the vein, and blood is drawn into an EDTA (lavender-top) or heparin (green-top) tube. These anticoagulants preserve the integrity of the red blood cells and prevent clotting, which is essential for accurate enzymatic analysis.
• Post-Collection Care: Once the required volume of blood is collected, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze to prevent hematoma formation. A small adhesive bandage is then applied.
• Duration and Experience: The entire venipuncture procedure takes less than five minutes. Patients may feel a brief, mild pinch as the needle enters the vein, but there is no lasting pain.
• Safety Considerations: All sample collections at Test Zone Diagnostic Center follow strict biosafety protocols, utilizing sterile, disposable equipment to eliminate any risk of cross-contamination or infection.

When is a G6PDH (Quantitative) Performed?

1. Evaluation of Neonatal Jaundice

Neonatal hyperbilirubinemia is a common condition, but severe, prolonged, or early-onset jaundice (occurring within the first 24 hours of birth) requires immediate investigation. G6PD deficiency is a major genetic cause of neonatal jaundice, particularly in male infants. If left untreated, excessively high levels of unconjugated bilirubin can cross the blood-brain barrier, leading to bilirubin-induced neurologic dysfunction or kernicterus, which causes permanent brain damage. Pediatricians request the G6PDH (Quantitative) test at Test Zone Diagnostic Center to rule out this enzymatic deficiency in newborns presenting with unexplained, severe jaundice, enabling timely intervention with phototherapy or exchange transfusion.

2. Unexplained Acute Hemolytic Anemia

When a patient presents with sudden-onset symptoms of hemolytic anemia—such as severe fatigue, pallor, dark tea-colored urine, rapid heart rate, and shortness of breath—physicians must rapidly identify the underlying cause. An acute hemolytic crisis can be triggered by infections, certain foods, or oxidative medications in G6PD-deficient individuals. The quantitative G6PD test helps hematologists and internists differentiate G6PD deficiency from other hemolytic anemias, such as autoimmune hemolytic anemia, hereditary spherocytosis, or sickle cell disease, guiding appropriate supportive care and the avoidance of triggering agents.

3. Prior to Initiating Oxidative Medications

Before prescribing medications known to induce oxidative stress in red blood cells, healthcare providers routinely order a G6PDH (Quantitative) test as a precautionary screening measure. High-risk drugs include primaquine and tafenoquine (used for malaria eradication), dapsone (used for leprosy and opportunistic infections), sulfamethoxazole (in co-trimoxazole), rasburicase (used for tumor lysis syndrome), and nitrofurantoin (used for urinary tract infections). Screening patients at Test Zone Diagnostic Center prior to drug administration prevents the accidental induction of severe, potentially life-threatening drug-induced hemolytic anemia.

4. History of Favism or Dietary Triggers

Favism is a clinical syndrome characterized by the rapid onset of severe hemolytic anemia within hours to days after consuming fava beans or inhaling pollen from the fava plant. This reaction is specific to individuals with certain variants of G6PD deficiency, particularly the Mediterranean variant (Class II). If a patient, especially a young child, experiences sudden illness, dark urine, and abdominal pain after eating fava beans, a physician will request a quantitative G6PD assay to confirm the diagnosis and provide definitive dietary counseling to prevent future life-threatening exposures.

5. Monitoring Post-Exposure Hemolysis

Infections (viral or bacterial) are among the most common triggers of hemolytic episodes in individuals with G6PD deficiency. During an infection, polymorphonuclear leukocytes release reactive oxygen species as part of the immune response, which can inadvertently cause oxidative damage to G6PD-deficient red blood cells. When a patient experiences a drop in hemoglobin levels or signs of hemolysis during or following an infectious illness (such as hepatitis, pneumonia, or typhoid), the G6PDH (Quantitative) test is performed to determine if an underlying enzyme deficiency contributed to the clinical deterioration.

What Does a G6PDH (Quantitative) Detect?

The G6PDH (Quantitative) test is highly sensitive and specific, detecting a wide spectrum of clinical states and physiological parameters related to erythrocyte metabolism, including:

• Severe G6PD enzyme deficiency (Class I), associated with chronic nonspherocytic hemolytic anemia.
• Moderate-to-severe G6PD deficiency (Class II), common in Mediterranean populations, predisposing patients to acute hemolytic crises from oxidative drugs, infections, or fava beans.
• Moderate G6PD deficiency (Class III), often seen in the A- variant (prevalent in African descent populations), where hemolysis is usually self-limiting as young red blood cells retain some enzyme activity.
• Normal G6PD enzyme activity (Class IV), indicating that any presenting hemolytic symptoms are likely due to other etiologies.
• Increased G6PD enzyme activity (Class V), a rare, clinically benign state with no associated pathology.
• Heterozygous carrier status in females, revealing intermediate enzyme levels that may fluctuate based on X-chromosome inactivation patterns.
• Susceptibility to drug-induced hemolytic anemia from specific oxidative agents.
• Susceptibility to favism (severe hemolysis triggered by fava bean ingestion).
• Susceptibility to infection-induced hemolysis during acute bacterial or viral illnesses.
• Risk of neonatal hyperbilirubinemia and potential kernicterus in newborns.
• The presence of a false-normal result due to recent blood transfusions.
• The presence of a false-normal result due to testing during an active hemolytic crisis with high reticulocytosis.
• Hemolytic risk associated with exposure to industrial chemicals, such as naphthalene (mothballs) or aniline dyes.
• Underlying cause of persistent unconjugated hyperbilirubinemia in pediatric and adult patients.
• Underlying cause of hemoglobinuria (free hemoglobin in the urine, causing dark color).
• Underlying cause of splenomegaly resulting from chronic extravascular hemolysis.
• Need for alternative therapeutic choices in patients requiring antimalarial or sulfone therapy.
• Baseline enzyme levels prior to high-dose intravenous Vitamin C therapy.
• Correlation with peripheral blood smear findings, such as Heinz bodies (denatured hemoglobin) and bite cells (degmacytes).
• Co-existence of G6PD deficiency with other hemoglobinopathies, such as thalassemia or sickle cell trait.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center in Lahore, Pakistan, we understand that timely diagnostic results are crucial for effective clinical decision-making. The G6PDH (Quantitative) test is processed in our advanced, fully automated pathology laboratory under strict quality control protocols. The standard turnaround time for this quantitative assay is typically 24 to 48 hours from the time of sample collection. Once the analysis is complete, the report undergoes a rigorous multi-level review by our consultant pathologists to ensure absolute accuracy. Patients and referring physicians are notified via SMS as soon as the report is ready. Reports can be accessed and downloaded online through our secure patient portal, or collected in person from our diagnostic center. This seamless digital access ensures that patients can promptly share their results with their consulting physicians for immediate medical guidance.

G6PDH (Quantitative) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
G6PD Enzyme Activity (Adults)	Normal activity (typically 7.0–20.5 U/g Hb, depending on laboratory reference range)	Decreased activity (deficient); indicates G6PD deficiency (Class I, II, or III)
G6PD Enzyme Activity (Infants)	Slightly higher than adults due to younger red cell population	Significantly decreased activity; indicates congenital G6PD deficiency and risk of neonatal jaundice
Reticulocyte Count	0.5% – 2.5% (normal red blood cell production)	Elevated (reticulocytosis); indicates active bone marrow response to hemolysis, can cause false-normal G6PD levels
Total & Unconjugated Bilirubin	Total: 0.2–1.2 mg/dL; Unconjugated: < 0.8 mg/dL	Elevated; indicates active hemolysis and impaired clearance, leading to clinical jaundice
Hemoglobin (Hb) Levels	Males: 13.5–17.5 g/dL; Females: 12.0–15.5 g/dL	Decreased; indicates anemia, which can be acute or chronic depending on the severity of the G6PD deficiency
Serum Haptoglobin	30–200 mg/dL	Markedly decreased or undetectable; indicates significant intravascular hemolysis
Peripheral Blood Smear	Normal erythrocyte morphology, no abnormal inclusions	Presence of Heinz bodies, bite cells (degmacytes), blister cells, and polychromasia (indicative of reticulocytes)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for G6PDH (Quantitative)?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists, hematologists, and technologists who specialize in metabolic and enzymatic assays.
• Patient-Focused Care: We prioritize patient comfort and safety, ensuring a compassionate, stress-free environment during sample collection.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to international quality standards, utilizing rigorous internal and external quality control programs.
• Professional Reporting: Our quantitative G6PD reports are detailed, precise, and structured to provide clear clinical utility for referring physicians.
• Modern Diagnostic Approach: We utilize state-of-the-art automated biochemistry and hematology analyzers to deliver highly reproducible and accurate quantitative results.
• Comfortable Environment: Our modern facility in Lahore is designed to offer a clean, hygienic, and welcoming atmosphere for all patients.
• Convenient Location: Located centrally in Lahore, Pakistan, our diagnostic center is easily accessible, offering ample parking and convenient operating hours.
• Commitment to Accurate Diagnosis: We are dedicated to providing precise diagnostic insights that form the foundation of effective patient management and preventive care.